{"id":168508,"date":"2024-02-14T02:39:37","date_gmt":"2024-02-14T07:39:37","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/telomir-pharmaceuticals-announces-closing-of-initial-public-offering\/"},"modified":"2024-08-18T11:47:40","modified_gmt":"2024-08-18T15:47:40","slug":"telomir-pharmaceuticals-announces-closing-of-initial-public-offering","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/telomir-pharmaceuticals-announces-closing-of-initial-public-offering.php","title":{"rendered":"Telomir Pharmaceuticals Announces Closing of Initial Public Offering"},"content":{"rendered":"<p><![CDATA[BALTIMORE, Feb.  13, 2024  (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (\u201cTelomir\u201d or the \u201cCompany\u201d), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA\u2019s protective telomere caps in order to affect age reversal, today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of\u00a0$7.00\u00a0per share. The gross proceeds to Telomir from the initial public offering were\u00a0$7 million, before deducting underwriting discounts and commissions and other offering expenses. All the shares of common stock were offered by Telomir. The shares began trading on The Nasdaq Capital Market on\u00a0February 9, 2024, under the ticker symbol \"TELO.\"]]><\/p>\n<p>Go here to read the rest:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/02\/13\/2828642\/0\/en\/Telomir-Pharmaceuticals-Announces-Closing-of-Initial-Public-Offering.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Telomir Pharmaceuticals Announces Closing of Initial Public Offering\">Telomir Pharmaceuticals Announces Closing of Initial Public Offering<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to read the rest: Telomir Pharmaceuticals Announces Closing of Initial Public Offering <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/telomir-pharmaceuticals-announces-closing-of-initial-public-offering.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-168508","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/168508"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=168508"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/168508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=168508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=168508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=168508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}